Le Lézard
Classified in: Tourism and vacations, Transportation, Covid-19 virus
Subjects: NEW PRODUCTS/SERVICES, TRAVEL

Global Crossing Airlines Enters Phase 2 for Certification of GlobalX-Colombia


MIAMI, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Global Crossing Airlines Group, Inc. (JET: NEO; JET.B: NEO; JETMF: OTCQB) (the "Company" or "GlobalX") is pleased to announce the start of Phase 2 of the Colombia AOC (Air Operators Certificate) Certification Process by GlobalX-Colombia. Initial approval from the Colombian CAA to start the formal certification was received in June of this year. GlobalX-Colombia is a 100% owned subsidiary of GlobalX and is led by Roberto Held, former CFO of Avianca and now a senior advisor to GlobalX who will become CEO of the subsidiary upon final certification.

In the coming weeks GlobalX-Colombia will be submitting all Flight Operations, and Maintenance/Technical Manuals for Phase 2 for review by the Colombian Civil Aviation Authority. The certification process is being led in Bogota by a team of experts and advisors with these matters. Final AOC approval is expected by the end of Q1 2023 when GlobalX will assign A321 freighters from its US operation to the Colombian AOC.

"We are committed to establishing an ACMI cargo charter airline based in Colombia to serve our growing list of Latin carriers and customers with our A321 freighter fleet," said Ed Wegel, Chairman and CEO of GlobalX. "We will become the first operator of the A321F in Latin America. This aircraft, with its greater volume capacity of 40% more than its nearest competitor, is an excellent option for Latin airlines and cargo forwarders who need less than widebody volume and cost on certain routes."

About Global Crossing Airlines

GlobalX is a US 121 domestic flag and supplemental Airline flying the Airbus A320 family aircraft. GlobalX flies as a passenger ACMI and charter airline serving the US, Caribbean, European and Latin American markets. In 2022, GlobalX will enter ACMI cargo service flying the A321 freighter, subject to DOT and FAA approvals. For more information, please visit www.globalxair.com.

For more information, please contact:
Ryan Goepel, CFO
Email: [email protected]

Cautionary Note Regarding Forward-Looking Information

This news release contains certain "forward looking statements" and "forward-looking information", as defined under applicable United States and Canadian securities laws, concerning anticipated developments and events that may occur in the future. Forward-looking statements contained in this news release include, but are not limited to, statements with respect to the Company's aircraft fleet size, the destinations that the Company intends to service, future demand for block hours, process and timeline for completion of the Colombia AOC process, the delivery and entry into service timelines for A321PCF aircraft, future demand and future A321PCF aircraft transactions.

In certain cases, forward-looking statements can be identified by the use of words such as "plans", "expects" "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved" suggesting future outcomes, or other expectations, beliefs, plans, objectives, assumptions, intentions or statements about future events or performance. Forward-looking statements contained in this news release is based on certain factors and assumptions regarding, among other things, the receipt of financing to continue airline operations, the accuracy, reliability and success of GlobalX's business model; GlobalX's ability to accurately forecast demand; GlobalX will be able to successfully conclude definitive agreements for transactions subject to LOI; the timely receipt of governmental approvals; the success of airline operations of GlobalX; GlobalX's ability to successfully enter new geographic markets; the legislative and regulatory environments of the jurisdictions where GlobalX will carry on business or have operations; the Company has or will have sufficient aircraft to provide the service; the impact of competition and the competitive response to GlobalX's business strategy; the future price of fuel, and the availability of aircraft. While the Company considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include risks related to, the ability to obtain financing at acceptable terms, the impact of general economic conditions, risks related to supply chain and labor disruptions, failure to retain or obtain sufficient aircraft, domestic and international airline industry conditions, failure to conclude definitive agreements for transactions subject to LOI, the effects of increased competition from our market competitors and new market entrants, passenger demand being less than anticipated, the impact of the global uncertainty created by COVID-19, future relations with shareholders, volatility of fuel prices, increases in operating costs, terrorism, pandemics, natural disasters, currency fluctuations, interest rates, risks specific to the airline industry, risks associated with doing business in foreign countries, the ability of management to implement GlobalX's operational strategy, the ability to attract qualified management and staff, labor disputes, regulatory risks, including risks relating to the acquisition of the necessary licenses and permits; risks related to significant disruption in, or breach in security of GlobalX's information technology systems and resultant interruptions in service and any related impact on its reputation; and the additional risks identified in the "Risk Factors" section of the Company's reports and filings with applicable Canadian securities regulators and the U.S. Securities and Exchange Commission. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those described in the forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements are made as of the date of this news release. Except as required by applicable securities laws, the Company does not undertake any obligation to publicly update any forward-looking statements. If GlobalX does update one or more forward-looking statements, no inference should be made that it will make additional updates with respect to those or other forward-looking statements.



These press releases may also interest you

at 09:35
Two large multi-state studies uncovered a highly effective way to improve antibiotic selection for patients hospitalized with pneumonia or urinary tract infections (UTI), enabling better antibiotic stewardship in hospitals, according to research...

at 09:25
The "The U.S. Telehealth Weight Loss Market" report from Marketdata LLC has been added to ResearchAndMarkets.com's offering The report includes in-depth analyses of: the scope of telehealth usage in the U.S., telehealth user demographics, pros and...

at 09:00
Amid growing concerns about a medical crisis as a result of acute conflict between the government...

at 08:45
Wolf Haldenstein Adler Freeman & Herz LLP  ("Wolf  Haldenstein") announces that a federal securities class action lawsuit has been filed in the United States District Court for the Southern  District of New York on behalf of investors who purchased...

at 08:00
Sunshine Biopharma Inc. , a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, is happy to announce that its wholly owned generic pharmaceutical subsidiary, Nora...

at 07:00
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against QuidelOrtho Corporation ("QuidelOrtho" or "the Company") for violations of 10(b) and 20(a) of the Securities...



News published on and distributed by: